[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN111410607B - Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same - Google Patents

Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same Download PDF

Info

Publication number
CN111410607B
CN111410607B CN202010282019.5A CN202010282019A CN111410607B CN 111410607 B CN111410607 B CN 111410607B CN 202010282019 A CN202010282019 A CN 202010282019A CN 111410607 B CN111410607 B CN 111410607B
Authority
CN
China
Prior art keywords
compound
formula
preparation
protecting group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010282019.5A
Other languages
Chinese (zh)
Other versions
CN111410607A (en
Inventor
陈冲
朱国良
杜小华
徐立
罗力军
王程翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Original Assignee
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Jiuzhou Pharmaceutical Co Ltd filed Critical Zhejiang Jiuzhou Pharmaceutical Co Ltd
Priority to CN202010282019.5A priority Critical patent/CN111410607B/en
Publication of CN111410607A publication Critical patent/CN111410607A/en
Application granted granted Critical
Publication of CN111410607B publication Critical patent/CN111410607B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of medicine synthesis, in particular to a preparation method of hexahydrofurofuranol derivatives, intermediates thereof and a preparation method thereof. The preparation method takes a compound of formula A1 or a compound of formula 0 as an initial raw material,
Figure DDA0002446961100000011
wherein R is 1 ，R 2 The same or different are alkyl groups. This is different from the starting materials reported in the prior patent literature and the specific preparation method is different from the prior patent literature, but the preparation method can industrially produce darunavir key intermediate (3R, 3aS,6 aR) -hexahydrofuro [2, 3-b)]-3-alcohols.

Description

Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same
Technical Field
The invention relates to the field of medicine synthesis, in particular to a preparation method of hexahydrofurofuranol derivatives, intermediates thereof and a preparation method thereof.
Background
The compound having the structure of formula Z below is the chemical name (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol:
Figure BDA0002446961090000011
belonging to one of hexahydrofurofuranol derivatives, and being an intermediate of darunavir as an anti-AIDS drug.
The Chinese patent application No. 200580010400.X of Taibolck pharmaceutical Co., ltd provides a preparation method of the (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol, wherein the starting material is a compound of the following formula (3),
Figure BDA0002446961090000012
a process for the preparation of the above-mentioned (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol is provided by Japanese Sumitomo chemical Co., ltd., chinese patent application No. 200380109926.4, wherein the starting material is a compound of the following formula VIII,
Figure BDA0002446961090000013
given that (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol is a key intermediate for the preparation of darunavir drugs, it is necessary to develop more preparation methods for the key intermediate. This requires development from different starting materials.
Disclosure of Invention
The method for preparing (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-alcohol starts from the selection of the starting materials, and researches and develops a preparation method for preparing darunavir key intermediates from the starting materials in the prior patent application. The preparation method provides another route suitable for industrialization for the preparation of the darunavir key intermediate.
In order to achieve the technical purpose of the invention, the invention provides the following technical scheme:
the first aspect of the present invention provides a compound of formula 1,
Figure BDA0002446961090000021
wave line
Figure BDA0002446961090000022
The representation can be +.>
Figure BDA0002446961090000023
S-configuration, also can be +.>
Figure BDA0002446961090000024
R configuration. Wherein R is L Is hydrogen or a hydroxyl protecting group. The hydroxyl protecting group is alkyl, silane, substituted phenyl or aryl.
The silane group is trimethylsilyl, triethylsilyl, tri-n-butylsilyl and tert-butyldimethylsilyl. The alkyl group is preferably a C1-C8 alkyl group. The aryl is phenyl, furyl, thienyl or indolyl. The substituted phenyl is alkyl substituted phenyl, alkoxyalkyl substituted phenyl, nitroalkyl substituted phenyl. The phenyl substituted by the alkyl is benzyl, benzhydryl and trityl; the phenyl substituted by the alkoxyalkyl is p-methoxybenzyl; the nitroalkyl-substituted phenyl is p-nitrobenzyl. The alkyl-substituted phenyl is preferably benzyl.
In particular, there is provided a compound of formula 1-1 or a compound of formula 1-2,
Figure BDA0002446961090000025
R L the same definition as above. Preferably, the compound is a compound,
Figure BDA0002446961090000031
in a second aspect the present invention provides a compound of formula 2,
Figure BDA0002446961090000032
wave line
Figure BDA0002446961090000033
The representation can be +.>
Figure BDA0002446961090000034
S-configuration, also can be +.>
Figure BDA0002446961090000035
R configuration. R is R L As in the case of the definition set forth above,
R 3 is alkyl. R is R L1 Is hydrogen or p-chlorobenzoyl.
In particular, compounds of formula 2-1 or compounds of formula 2-2 are provided,
Figure BDA0002446961090000036
wherein R is 3 Is alkyl.
Preferably, the compound is a compound,
Figure BDA0002446961090000037
in a third aspect the present invention provides a compound of formula B,
Figure BDA0002446961090000041
in particular, the following compounds of formula B-1,
Figure BDA0002446961090000042
wherein R is 1 ，R 2 Hydrogen, identical or different, being carboxyl protecting groups, e.g. alkylSubstituted phenyl groups such as alkyl-substituted phenyl, alkoxyalkyl-substituted phenyl, nitroalkyl-substituted phenyl or silane groups; r is R L The same definition as above.
The alkyl group being C 1 -C 8 Alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; the phenyl substituted by the alkyl is benzyl, benzhydryl and trityl; the phenyl substituted by the alkoxyalkyl is p-methoxybenzyl; the nitroalkyl-substituted phenyl is p-nitrobenzyl and the like, preferably methyl, isopropyl, tert-butyl and benzyl; the silane group is trimethylsilyl, triethylsilyl, tri-n-butylsilyl and tert-butyldimethylsilyl; the aryl is phenyl, furyl, thienyl or indolyl.
In a fourth aspect, the present invention provides a process for the preparation of a compound of formula B and a compound of formula B-1, wherein the compound of formula B-1 is prepared by reacting a compound of formula A1 with a compound of formula A2, wherein the compound of formula B is the same as the compound of formula A1, and the compound of formula A1 is adjusted to its racemate,
Figure BDA0002446961090000043
wherein R is 1 ，R 2 ，R L As defined above, X is a leaving group.
X may be a halogen atom, preferably an iodine atom, a bromine atom; methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, benzenesulfonyloxy.
Specifically, the protecting group R is prepared L A compound of formula B-1 which is tert-butyl,
Figure BDA0002446961090000051
wherein R is 1 ，R 2 X is as defined above.
Specifically, the protecting group R is prepared L A compound of formula B-1 which is trimethylsilyl,
Figure BDA0002446961090000052
wherein R is 1 ，R 2 X is as defined above.
Specifically, the protecting group R is prepared L A compound of formula B-1 which is benzyl,
Figure BDA0002446961090000053
wherein R is 1 ，R 2 X is as defined above.
Specifically, the protecting group R is prepared L A compound of formula B-1 which is benzhydryl,
Figure BDA0002446961090000054
wherein R is 1 ，R 2 X is as defined above.
Wherein, the compound of the formula B-1 with the protecting group being hydrogen can be prepared by deprotection of a protecting group which is alkyl, benzyl or alkyl silicon base. For example, alkyl groups are hydrolyzed to hydroxyl groups by acid, benzyl groups are deprotected to hydroxyl groups by palladium on charcoal, and alkyl silicon groups are deprotected to hydroxyl groups by acid such as trifluoroacetic acid.
The reaction for preparing the compound of formula B-1 is carried out in the presence of a base. The alkali is alkyl lithium or a compound with the following structure,
Figure BDA0002446961090000061
wherein L is 1 ，L 2 Is alkyl, cycloalkyl, alkylsilyl, M is a metal atom such as lithium, potassium, sodium, etc.
Specifically, the alkali is lithium diisopropylamide, lithium cyclohexylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide or n-butyllithium.
Preferably, the base is lithium diisopropylamide.
The amount of the base to be used is usually 2.0 to 3.5mol, preferably 2.2 to 3.0mol, relative to 1mol of the compound of the formula A1.
The reaction solvent is an ether solvent such as diethyl ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran, methyl tetrahydrofuran, etc.
The reaction temperature is-78 ℃ to 70 ℃, preferably-78 ℃ to 0 ℃.
Wherein the compound of formula B-1 prepared by the reaction of the compound of formula A1 and the compound of formula A2 exists in a majority of the following configuration,
Figure BDA0002446961090000062
in the form of its diastereoisomers,
Figure BDA0002446961090000063
the person skilled in the art can purify the compounds of formula B-1 herein by column chromatography or the like,
Figure BDA0002446961090000071
more preferably, however, the compounds of formulas 1-2 are prepared directly for the following reaction without purification.
That is, the fifth aspect of the present invention provides a process for preparing a compound of formula 1-2, from a compound of formula B-1 by reduction and cyclization.
Figure BDA0002446961090000072
Wherein, since the above compound of formula B-1 exists mostly in the following configuration,
Figure BDA0002446961090000073
after that, most of the compounds of the formula 1-2 are formed,
Figure BDA0002446961090000074
the minority is present in a configuration such that,
Figure BDA0002446961090000081
the reducing agent may be a reducing agent known in the art for reducing carbonyl groups to hydroxyl groups. Such as boron-based reducing agents or aluminum-based reducing agents. The cyclization reagent may be an acid. The acid is an inorganic acid or an organic acid. The inorganic acid is hydrochloric acid or sulfuric acid, and the organic acid is trifluoroacetic acid.
In a sixth aspect, the present invention provides a process for the preparation of a compound of formula 1-1. Is prepared by reacting a compound of formula 0 with a compound of formula A2.
Figure BDA0002446961090000082
In particular, R is prepared L A compound of formula 1-1 which is tert-butyldisilyl,
Figure BDA0002446961090000083
the reaction for preparing the compound of formula 1-1 is carried out in the presence of a base. The alkali is alkyl lithium or a compound with the following structure,
Figure BDA0002446961090000084
wherein L is 1 ，L 2 Is alkyl, cycloalkyl, alkylsilyl, M is a metal atom such as lithium, potassium, sodium, etc.
Specifically, the alkali is lithium diisopropylamide, lithium cyclohexylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, lithium hexamethyldisilazide or n-butyllithium.
Preferably, the base is lithium hexamethyldisilazide or lithium diisopropylamide.
The amount of the base to be used is usually 2.0 to 3.5mol, preferably 2.2 to 3.0mol, relative to 1mol of the compound of formula 0.
The reaction solvent is an ether solvent such as diethyl ether, isopropyl ether, methyl tertiary butyl ether, tetrahydrofuran, methyl tetrahydrofuran, etc.
The reaction temperature is-78 ℃ to 70 ℃, preferably-78 ℃ to 0 ℃.
In a seventh aspect the invention provides a compound of formula 2, in particular R L1 A process for the preparation of a compound of formula 2-1 or formula 2-2 which is hydrogen. Is prepared by substituting and reducing a compound of formula 1 or a compound of formula 1-2. The reaction formula is as follows:
Figure BDA0002446961090000091
wherein the reducing agent may be a reducing agent known in the art for reducing carbonyl groups to hydroxyl groups. Such as boron-based reducing agents, aluminum-based reducing agents, and the like. The boron-based reducing agent can be boron trifluoride, sodium borohydride or boron trifluoride diethyl ether; the aluminum reducing agent can be lithium aluminum hydride, red aluminum, lithium diisobutyl aluminum hydride and the like.
The reaction solvent is alcohol solvent such as methanol and ethanol.
The substitution in the above reduction reaction may be reacted with p-chlorobenzoyl chloride, wherein R L1 Is p-chlorobenzoyl.
In an eighth aspect, the present invention provides a process for the preparation of the key intermediate (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol of darunavir and (3R, 3aS,6 aS) -hexahydrofuro [2,3-b ] -3-ol. Is prepared from the compound of formula 2 through hydrolysis reaction. The reaction formula is as follows:
Figure BDA0002446961090000101
specifically, the compound is prepared by hydrolysis reaction of a compound of formula 2-1,
Figure BDA0002446961090000102
specifically, the compound is prepared by hydrolysis reaction of a compound of formula 2-2,
Figure BDA0002446961090000103
the hydrolysis reagents of the hydrolysis reaction may be acids or bases well known in the art. The acid may be an inorganic acid or an organic acid. The inorganic acid is hydrochloric acid or sulfuric acid; the organic acid is trifluoroacetic acid.
(3R, 3aS,6 aS) -hexahydrofuro [2,3-b ] -3-ol the key intermediate (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol of darunavir can be prepared by methods in the prior literature. Such as in journal literature Bioorganic & Medicinal Chemistry Letters (1996), 6 (23), 2847-2852.
Figure BDA0002446961090000104
Wherein R is 4 Is phenyl, p-nitrophenyl, methyl, or-NH- (R) -1- (1-naphthalene) ethyl.
Further, (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-ol and (3R, 3aS,6 aS) -hexahydrofuro [2,3-b ] -3-ol can be prepared by a one-pot method through the compound of the formula 1. I.e., reduction reaction, hydrolysis reaction is carried out in one pot without isolating the compound of formula 2.
One preferred embodiment of the present invention is:
Figure BDA0002446961090000111
another preferred embodiment of the present invention is:
Figure BDA0002446961090000112
wherein R is L Preferably t-butyl or benzyl, R L1 P-chlorobenzoyl is preferred.
In a ninth aspect the present invention provides a compound of formula C,
Figure BDA0002446961090000113
comprising a compound of formula C1 and a compound of formula C2,
Figure BDA0002446961090000114
in a tenth aspect the present invention provides a process for the preparation of a compound of formula C, from a compound of formula B.
Since the above-mentioned compounds of formula B-1 are present for the most part in the following configuration,
Figure BDA0002446961090000115
the resulting compound of formula C, after that reaction, is also present in the following configuration,
Figure BDA0002446961090000121
the minority is present in a configuration such that,
Figure BDA0002446961090000122
wherein when R is 2 In the case of hydrogen, the reaction can be completed through three processes of deprotection, cyclization and hydrolysis, or through hydrolysis, deprotection and cyclization, or through deprotection, hydrolysis and cyclization. I.e. these three processes are in any order.
Figure BDA0002446961090000123
The deprotection reagent is acid or palladium carbon, and the cyclization reagent can be acid, wherein the acid is inorganic acid or organic acid; the hydrolysis reagent is an inorganic base.
The inorganic acid is hydrochloric acid or sulfuric acid; the organic acid is trifluoroacetic acid, and the inorganic base is sodium hydroxide, sodium carbonate and the like.
The compound of the formula C can also be prepared by reacting the compound of the formula A1 with the compound of the formula A2, then deprotecting, cyclizing and hydrolyzing in any sequence,
Figure BDA0002446961090000124
the invention relates to a method for preparing darunavir key intermediate (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-alcohol, which takes a compound of formula A1 or a compound of formula 0 as a starting material,
Figure BDA0002446961090000131
wherein R is 1 ，R 2 The same definition as above. This is different from the starting materials reported in the prior patent literature, and the specific preparation method is also different from the prior patent literature, but the preparation method can industrially produce darunavir as the key intermediate.
Detailed Description
In order to further understand the present invention, the following describes in detail the preparation method of hexahydrofurofuranol derivative, its intermediate and its preparation method provided in the present invention with reference to examples. It should be understood that these examples are presented merely to further illustrate the features of the present invention and are not intended to limit the scope of the invention or the scope of the claims.
Example 1: preparation of (3R) -diisopropyl-2- (2- (tert-butoxy) -ethyl) -3-hydroxy
Figure BDA0002446961090000132
63ml of LDA (2.1 eq) and 30ml of THF are added into a 250ml four-mouth bottle equipped with a magnetic stirrer and a thermometer under the protection of nitrogen, cooled to-60 ℃ to-70 ℃, isopropyl malate (13.1 g,60 mmol) is dropwise added, the temperature is controlled to be not higher than-60 ℃, the internal temperature is maintained for stirring for 30min after the dropwise addition, the temperature is slowly increased to-20 ℃ for half an hour, the temperature is reduced to-60 ℃ to-70 ℃, 2-iodoethyl tert-butyl ether (27.4 g,2.0 eq) is dropwise added after the dropwise addition, the temperature is maintained for half an hour after the dropwise addition, and the mixture is stirred overnight at-20 ℃. The reaction system was stirred for 5min with 90ml of water and 40ml of ethyl acetate, the layers were allowed to stand, the aqueous phase was extracted with (40 ml. Times.3) ethyl acetate, the combined organic layers were dried over magnesium sulfate, filtered and concentrated to give 28.54g of an oil, and the fractions were isolated by column to determine the title compound in 80% yield. The product spectrum data are as follows:
1 H NMR(400.2MHz,CDCl 3 )δ5.10(1H,m),5.01(1H,m),4.31(1H,m)，3.54(1H,d，J＝7.2Hz),3.46(2H,m),3.06(1H,m)，2.13(1H,m),1.86(1H,m)，1.29(6H,d，J＝2.8Hz)，1.27(6H,d，J＝2.8Hz),1.18(9H,s)；
13 C NMR(100.6MHz,CDCl 3 ) Delta 172.8 (d, j=8.8 Hz), 171.45 (d, j=36.8 Hz), 72.83 (d, j=5.9 Hz), 71.18 (d, j=37.3 Hz), 69.48 (t, j=8.2 Hz), 68.1 (d, j=8.2 Hz), 58.88(s), 45.67 ppm(s), 28.59(s), 27.34 ppm(s), 21.58 ppm(s); mass Spectrometry (ESI method) C 16 H 30 O 6 (M) + Calculated 318.20 measured 319.2
Example 2: preparation of (3R) -diethyl-2- (2- (tert-butoxy) -ethyl) -3-hydroxy
Figure BDA0002446961090000141
In a 250ml four-mouth bottle equipped with a magnetic stirrer and a thermometer, 42ml LDA (2.1 eq) and 20ml THF are added under the protection of nitrogen, cooled to-60 ℃ to-70 ℃, ethyl malate (7.5 g,40 mmol) is dropwise added, the temperature is controlled to be not more than-60 ℃, the internal temperature is maintained for stirring for 30min after the dropwise addition, the temperature is slowly increased to-20 ℃ for half an hour, the temperature is reduced to-60 ℃ to-70 ℃, 2-iodoethyl tert-butyl ether (9.58 g,2.0 eq) is dropwise added, the temperature is maintained for half an hour after the dropwise addition, and the temperature is increased to-20 ℃ after the dropwise addition and stirring is completed for overnight. The reaction system was stirred for 5min with 90ml of water and 40ml of ethyl acetate, the layers were allowed to stand, the aqueous phase was extracted with (40 ml. Times.3) ethyl acetate, the combined organic layers were dried over magnesium sulfate, filtered and concentrated to give 7.49g of an oil, and the fractions were isolated by column to determine the title compound in 60% yield. The product spectrum data are as follows:
1 H NMR(400.2MHz,CDCl 3 )δ4.30(1H,m),4.20(2H,m),4.11(2H,m)，3.52(1H,m),3.49(2H,m),3.10(1H,m)，2.12(1H,m),1.88(1H,m)，1.31(6H,d，J＝2.8Hz)，1.27(6H,d，J＝2.8Hz),1.15(9H,s)。
example 3: preparation of (3R) -diisopropylmethyl-2- (2- (trimethylsiloxy) -ethyl) -3-hydroxy
Figure BDA0002446961090000142
Compounds of formula B-1 wherein the protecting group is trimethylsilyl can be prepared as in example 1 or 2.
Example 4:
Figure BDA0002446961090000151
compounds of formula B-1 wherein the protecting group is benzyl can be prepared as in example 1 or 2.
Example 5:
Figure BDA0002446961090000152
the compound of the formula B-1 with the protecting group being hydrogen can be prepared through deprotection, and the product spectrogram data are as follows:
1 H NMR(400.2MHz,CDCl 3 )δ5.14(1H,m),5.04(1H,m),4.53(2H,m)，4.28(1H,s),3.22(1H,m),3.02(1H,m)，2.60(1H,m),2.35(1H,m)，1.29(6H,m)，1.25(6H,m)；
mass Spectrometry (ESI method) C 12 H 22 O 6 (M) + Calculated 262.29 measured 263.2.
Example 6: preparation of Compounds of formula C
To a 50ml two-necked flask were added 300mg of (3R) -diisopropyl-2- (2- (t-butoxy) -ethyl) -3-hydroxy and 1ml of trifluoroacetic acid, cooled to-10 ℃ to-5 ℃ and stirred overnight, the trifluoroacetic acid was distilled off at low temperature, aqueous sodium hydroxide solution and tetrahydrofuran were added and stirred at room temperature for 6 hours, then diluted hydrochloric acid was used to adjust pH=2, extraction was performed with ethyl acetate, the solvent was evaporated, toluene was added and evaporated to dryness at normal pressure, this operation was repeated 2 times to obtain 127mg of a white solid with a yield of 80%, and the nuclear magnetic resonance was identified as the target compound. The product spectrum data are as follows:
1 H NMR(400.2MHz,DMSO-d 6 )δ4.25(3H,m),3.13(1H,m),2.33(1H,m)，2.13(1H,m)。
mass Spectrometry (ESI method) C 6 H 8 O 5 (M) - Calculated 160.1 measured 159.1.
Example 7:
Figure BDA0002446961090000153
R L is tert-butyl
Adding sodium borohydride, THF and nitrogen gas into a reaction bottle, cooling to-10-15 ℃ under the protection of nitrogen gas, stirring, and dropwise adding R under the protection of nitrogen gas L The temperature of the compound of formula B/THF solution is controlled to be-10 to-5 ℃. After the dripping is finished, preserving heat, beginning to drip acetic acid, controlling the temperature to-10 to-5 ℃, and heating to 20 to 25 ℃ for preserving heat. After heat preservation, coolDropwise adding water to-10-5 ℃, controlling the temperature to-10-5 ℃, stirring until the TLC raw materials are reacted, heating to 0-5 ℃, adding dichloromethane for extraction, layering, concentrating an organic layer at 50-55 ℃ under reduced pressure to obtain 16.5g of oily matter, adding the obtained oily matter into a reaction bottle, adding THF, p-toluenesulfonic acid, stirring, heating to 75-80 ℃ for reflux for 16-18h, and finishing the TLC raw materials reaction. Cooling, concentrating under reduced pressure at 55-60deg.C to obtain non-dripping distillate, cooling to 0-5deg.C, adding water and DCM, stirring, layering, and collecting organic layer, concentrating under reduced pressure at 50-55deg.C to obtain oily substance with yield of 11.7g and 80%.
Example 8:
Figure BDA0002446961090000161
R L1 r is p-chlorobenzoyl L Is tert-butyl
The oil from example 7, DCM, p-chlorobenzoyl chloride and triethylamine were added dropwise while stirring in a reaction flask, the temperature was controlled at 20-25℃and TLC was run to completion. Cooled, 100ml of water was added, and the mixture was allowed to stand and delaminated. The organic layer was concentrated under reduced pressure at 55-60℃to remove the solvent, and then crystallized with EA and hexane to give 20g of the product in 90% yield. The crystallization product is put into a reaction bottle, stirred and cooled to-65 ℃ to-70 ℃ under the protection of THF nitrogen, lithium diisobutyl aluminum hydride is added dropwise, and TLC is carried out until the reaction of the raw materials is completed. Cooled, 100ml of methanol, 10g of boron trifluoride diethyl etherate are added, stirred for 16-18h at 20-25 ℃ and concentrated to a non-dripping distillation liquid at 50-55 ℃ under reduced pressure, 28g of product is obtained, and the (3R, 3aS,6 aR) -hexahydrofuro [2,3-b ] -3-alcohol can be directly prepared without separation.
Example 9:
Figure BDA0002446961090000162
R L1 r is p-chlorobenzoyl L Into a reaction flask was charged a compound of formula 2-2 (R L1 R is p-chlorobenzoyl L Tert-butyl), THF, hydrochloric acid and water at 0-5deg.C until the raw materials disappear, cooling, adding dichloromethane, extracting, layering, collecting organic layer, and concentrating under reduced pressure at 50-55deg.C until no dripping occursThe liquid is used to obtain the product (3R, 3aS,6 aR) -hexahydrofuro [2,3-b]-3-ol 7.8g. The total yield was 87%.
Example 10:
Figure BDA0002446961090000171
15g of the compound of formula 0, DMPU18.8g and THF10ml are placed in a four-necked flask. N (N) 2 And (3) protecting, cooling to-78 to-80 ℃, and dripping 407ml of HMDSLi. Controlling the temperature to be between 70 ℃ below zero and 65 ℃ below zero, and preserving the temperature for 1h after dripping. 15.4g of 2-iodoethyl tert-butyl disilyl ether as a compound of the formula A is added dropwise, and the temperature is controlled between-65 ℃ and-60 ℃. After incubation for 4h, TLC starting material was completed, quenched with 30ml of saturated aqueous NaCl and the aqueous layer was extracted with 20ml of ethyl acetate as a layer. The organic layers were combined and concentrated to dryness to give the desired product in 75% yield and 98% purity.
DMPU is 1, 3-dimethyl-3, 4,5, 6-tetrahydro-2-pyrimidinone, HMDSLi: lithium hexamethyldisilazide
Example 11:
Figure BDA0002446961090000172
the compound of formula 1-1 (R) L Tertiary butyl disilyl group), THF, cooling to-65- -70 ℃ under the protection of nitrogen, dropwise adding diisobutyl aluminum lithium hydride, TLC until the reaction of the raw materials is finished, adding 100ml of methanol, 10g of boron trifluoride diethyl ether, stirring for 16-18h at 20-25 ℃, concentrating under reduced pressure at 50-55 ℃ to remove the solvent, and extracting 21.4g of the product with DCM to obtain the product with the yield of 85%.
DCM: dichloromethane (dichloromethane)
Example 12:
Figure BDA0002446961090000173
into a 250ml four-necked flask, 2-1 compound (R L Tertiary butyl disilyl group), THF, cooling to 0-5 ℃ and adding 10g of 30% hydrochloric acid, reacting at 0-5 ℃ until the raw material disappears, adding sodium bicarbonate to neutralize to ph=7-8, filtering to remove solidsAdding DCM, extracting and then removing the solvent to obtain (3R, 3aS,6 aS) -hexahydrofuro [2,3-b]7.99g of 3-ol, yield 85%.

Claims (4)

1. The preparation method of the compound of the formula C is characterized in that the compound of the formula B is prepared by deprotection, cyclization and hydrolysis in any order,
Figure FDA0004059735190000011
wherein R is 1 ，R 2 Is hydrogen or the same or different is carboxyl protecting group, wherein the carboxyl protecting group is alkyl, silane or substituted phenyl, R L Is hydrogen or a hydroxyl protecting group; the hydroxyl protecting group is alkyl, silane, substituted phenyl or aryl.
2. The preparation method of the compound of the formula C is characterized in that the compound of the formula A1 and the compound of the formula A2 are reacted and then subjected to deprotection, cyclization and hydrolysis in any sequence to prepare the compound of the formula C by one-pot reaction,
Figure FDA0004059735190000012
wherein R is 1 ，R 2 R is as defined in claim 1 L Is hydrogen or a hydroxyl protecting group; the hydroxyl protecting group is alkyl, silane, substituted phenyl or aryl.
3. The process of claim 1, wherein the compound of formula B is prepared by reacting a compound of formula A1 with a compound of formula A2,
Figure FDA0004059735190000013
wherein R is 1 ，R 2 ，R L As defined in claim 1Similarly, X is a leaving group, and the leaving group is a halogen atom, such as methanesulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, benzenesulfonyloxy.
4. The process according to claim 3, wherein X is an iodine atom and R 1 ，R 2 Methyl, ethyl, isopropyl, tert-butyl, benzyl, which are identical or different; the R is L Is tert-butyl, trimethylsilyl, benzyl, benzhydryl.
CN202010282019.5A 2015-09-08 2016-08-24 Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same Active CN111410607B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010282019.5A CN111410607B (en) 2015-09-08 2016-08-24 Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/089162 2015-09-08
PCT/CN2015/089162 WO2017041228A1 (en) 2015-09-08 2015-09-08 Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof
CN202010282019.5A CN111410607B (en) 2015-09-08 2016-08-24 Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same
CN201610726487.0A CN106496263B (en) 2015-09-08 2016-08-24 Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201610726487.0A Division CN106496263B (en) 2015-09-08 2016-08-24 Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

Publications (2)

Publication Number Publication Date
CN111410607A CN111410607A (en) 2020-07-14
CN111410607B true CN111410607B (en) 2023-05-09

Family

ID=58240501

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010282019.5A Active CN111410607B (en) 2015-09-08 2016-08-24 Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same
CN201610726487.0A Active CN106496263B (en) 2015-09-08 2016-08-24 Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610726487.0A Active CN106496263B (en) 2015-09-08 2016-08-24 Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate

Country Status (2)

Country Link
CN (2) CN111410607B (en)
WO (1) WO2017041228A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043385B (en) * 2016-02-05 2019-07-09 成都博腾药业有限公司 A method of preparing darunavir intermediate

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1425658A (en) * 2001-12-14 2003-06-25 中国科学院成都有机化学研究所 Synthetic method for (S)-3-hydroxy-gamma-butyrolactone
WO2004002975A1 (en) * 2002-06-27 2004-01-08 Smithkline Beecham Corporation PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL
WO2004060895A1 (en) * 2002-12-27 2004-07-22 Sumitomo Chemical Company, Limited Process for producing hexahydrofurofuranol derivative, intermediate thereof and process for producing the same
CN1753898A (en) * 2002-12-27 2006-03-29 住友化学株式会社 Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof
CN1887880A (en) * 2006-07-20 2007-01-03 厦门大学 Synthesis of S-(3)-hydroxy tetrahydrofuran
CN1938316A (en) * 2004-03-31 2007-03-28 泰博特克药品有限公司 Methods for the preparation of (3r,3as,6ar) hexahydro-furo[2,3-b]furan-3-ol
CN1989106A (en) * 2004-07-26 2007-06-27 应用研究系统Ars股份公司 N-hydroxyamide derivatives and their use
CN101172980A (en) * 2001-09-10 2008-05-07 泰博特克药品有限公司 Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CN103896886A (en) * 2012-12-31 2014-07-02 上海迪赛诺化学制药有限公司 Darunavir midbody as well as preparation method and application thereof
CN104520262A (en) * 2012-08-09 2015-04-15 住友化学株式会社 Method for producing hexahydrofurofuranol derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864813B (en) * 2012-12-18 2017-02-22 上海迪赛诺化学制药有限公司 Synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and enantiomer thereof
CN107043385B (en) * 2016-02-05 2019-07-09 成都博腾药业有限公司 A method of preparing darunavir intermediate
CN107344944B (en) * 2016-05-07 2021-03-05 成都博腾药业有限公司 Method for preparing darunavir intermediate

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101172980A (en) * 2001-09-10 2008-05-07 泰博特克药品有限公司 Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CN1425658A (en) * 2001-12-14 2003-06-25 中国科学院成都有机化学研究所 Synthetic method for (S)-3-hydroxy-gamma-butyrolactone
WO2004002975A1 (en) * 2002-06-27 2004-01-08 Smithkline Beecham Corporation PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL
WO2004060895A1 (en) * 2002-12-27 2004-07-22 Sumitomo Chemical Company, Limited Process for producing hexahydrofurofuranol derivative, intermediate thereof and process for producing the same
CN1753898A (en) * 2002-12-27 2006-03-29 住友化学株式会社 Production method of hexahydrofurofuranol derivative, intermediate therefor and production method thereof
CN1938316A (en) * 2004-03-31 2007-03-28 泰博特克药品有限公司 Methods for the preparation of (3r,3as,6ar) hexahydro-furo[2,3-b]furan-3-ol
CN1989106A (en) * 2004-07-26 2007-06-27 应用研究系统Ars股份公司 N-hydroxyamide derivatives and their use
CN1887880A (en) * 2006-07-20 2007-01-03 厦门大学 Synthesis of S-(3)-hydroxy tetrahydrofuran
CN104520262A (en) * 2012-08-09 2015-04-15 住友化学株式会社 Method for producing hexahydrofurofuranol derivative
CN103896886A (en) * 2012-12-31 2014-07-02 上海迪赛诺化学制药有限公司 Darunavir midbody as well as preparation method and application thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"189. Further Syntheses of Optically Active Verrucarinic Acid";Peter Grossen et al.;《HELVETICA CHIMICA ACTA》;19841231;第67卷;第1625-1629页 *
"EVALUATION OF FUROFURAN AS A P2 LIGAND FOR SYMMETRY-BASED HIV PROTEASE INHIBITORS";Xiaoqi Chen et al.;《Bioorganic & Medicinal Chemistry Letters》;19961231;第6卷(第23期);第2847-2852页 *
"Substrate Activity of Structural Analogs of Isocitrate for Isocitrate Dehydrogenases from Bovine Heart";Gerhard W. E. Plaut et al.;《BIOCHEMISTRY》;19751231;第14卷(第12期);第2581-2588页 *
"Substrate specificity analysis and inhibitor design of homoisocitrate dehydrogenase";Takashi Yamamoto et al.;《Bioorganic & Medicinal Chemistry》;20061109;第15卷;第1346-1355页 *
"Syntheses with a Chiral Building Block from the Citric Acid Cycle:(2R,3S)-Isocitric Acid by Fermentation of Sunflower Oil";Philipp Heretsch et al.;《Angew. Chem. Int. Ed.》;20080131;第47卷;第1958-1960页 *
"Synthesis of Cyclopropane Substrate Analog for 3-Isopropylmalate Dehydrogenase and Its Mechanism-Based Inhibition";Akira Chiba et al.;《Tetrahedron》;19991231;第55卷;第2927-2936页 *
"Synthetic and Mechanistic Studies of (2R,3S)-3-Vinylmalic Acid as a Mechanism-Based Inhibitor of 3-Isopropylmalate Dehydrogenase";Akira Chiba et al.;《J. Org. Chem.》;19990508;第64卷(第17期);第6159-6165页 *
"Total Synthesis of (−)-Goniomitine";Shiqiang Zhou et al.;《Org. Lett.》;20140602;第16卷;第3416-3418页 *
"Total Synthesis of Citrafungin A";Frederick Calo et al.;《J. Org. Chem.》;20080410;第73卷(第24期);第9692-9697页 *

Also Published As

Publication number Publication date
CN111410607A (en) 2020-07-14
CN106496263B (en) 2020-10-30
WO2017041228A1 (en) 2017-03-16
CN106496263A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
US20060116519A1 (en) Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
JP6573848B2 (en) Method for synthesizing entecavir and intermediate compound thereof
TWI540121B (en) Method and novel intermediate for preparing treprostinil diethanolamine
CN103703014A (en) Process for the production of estetrol intermediates
JP2005516064A (en) Method for producing organic compound
JP2007538041A (en) Method for producing diphenylazetidinone derivative
CN111410607B (en) Process for preparing hexahydrofurofuranol derivative, intermediate and process for preparing the same
EP3166918B1 (en) Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy- cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs
KR20100046007A (en) Process for the production of tertiary alcohols
EP3986400B1 (en) Processes and intermediates for producing diazaspiro lactam compounds
EP4130020A1 (en) Novel method for preparing inotodiol
US8242288B2 (en) Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the method
JP4588989B2 (en) Process for producing 5-formyl-2-furylboric acid
CN107304194A (en) The method for preparing Dapagliflozin
EP0478062A1 (en) In-situ preparation of diisopinocampheyl chloroborane
JP2008094744A (en) Process for producing piperidin-4-one derivative using bisaminol ether compound
WO2018108130A1 (en) Process for preparation of novel androgen receptor antagonist
KR101009467B1 (en) Taxan derivative useful for synthesizing docetaxel and a method for preparing the same
JP2016517897A (en) Aminoaryl-boronic acids and esters and methods for producing aminoheteroaryl boronic acids and esters
WO2007023503A1 (en) A process for the preparation of fluvastatin sodium
CN107987096B (en) Method for synthesizing 2-aldehyde furan-4-boronic acid pinacol ester
JPH1017561A (en) Allylalcohol compounds and their production
KR100408431B1 (en) Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one or pharmaceutically acceptable salts thereof
AU737502B2 (en) Preparation of beta-methyl carbapenem intermediates
JP2002539205A (en) Improved process for asymmetric hydrogenation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant